Navigation Links
Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
Date:3/11/2011

BURLINGAME, Calif., March 11, 2011 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) of China to evaluate APX003 (also known as BD0801) as a potential cancer therapy.  APX003 is a humanized monoclonal antibody directed against VEGF, and is intended for the treatment of multiple malignancies.  Upon review and approval of the IND application by the SFDA, Simcere plans to initiate Phase 1 safety and tolerability studies in cancer patients.

Simcere will develop and commercialize APX003 in China under a license agreement with Apexigen.  In 2008, Simcere acquired rights to APX003 from Epitomics, Inc.  Then in July of 2010, Epitomics created Apexigen as an independent therapeutic antibody company, licensed to Apexigen exclusive rights to the use of its antibody technologies for the development and commercialization of antibody therapeutics, and assigned to Apexigen the license and collaboration agreement with Simcere.  Apexigen and Simcere collaborated on the IND enabling studies and on the completion of the IND for APX003.

The initiation of this Phase 1 clinical study will mark a significant milestone for Apexigen.  APX003 will be the first humanized antibody generated through the use of its technology to be administered to humans.  

"This is an exciting time for Apexigen.  We are eager to see the first of our antibodies demonstrate safety, tolerability and efficacy in man as a first step toward the development of best-in-class therapeutics," said Dr. Xiaodong Yang, President & CEO of Apexigen.  "The collaboration with Simcere has been very productive.  We look forward to continuing to collaborate with Simcere on the clinical development program which will provide the first clinical validation of our technology."

"This IND filing is the outcome of dedicated effort and collaboration between Apexigen and Simcere," said Mr. Jinsheng Ren, chairman and chief executive officer of Simcere.

About Apexigen, Inc.

Apexigen, Inc. is an emerging biopharmaceutical company focusing on the development of monoclonal antibodies as best-in-class therapeutics. Apexigen's antibody technologies produce a broad diversity of antibodies with high specificity, high affinity, and unique epitopes, and can successfully generate antibodies against challenging antigens where competing technologies fail.

Located in Burlingame, CA, Apexigen owns exclusive rights, for use in the development and commercialization of human therapeutics, to the proprietary antibody technologies and therapeutic antibodies developed by Epitomics, Inc.  Apexigen is actively developing its internal therapeutic product pipeline and seeking to form collaborative relationships with pharmaceutical and biotechnology companies for the discovery and development of pharmaceutical products based on its humanized rabbit monoclonal antibody technologies.  More information about Apexigen is available at www.apexigen.com.ContactsApexigenMark NevinsVice President, Business Development+1 650 931-6236 ext. 502
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon Hemopurifier® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
(Date:2/21/2017)... Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... results for the three months ended December 31, 2016. ... life sciences and diagnostics company that develops and commercializes proprietary ... ... build on the commercial milestones achieved in fiscal 2016," said ...
(Date:2/21/2017)... Basel, Switzerland (PRWEB) , ... February 21, 2017 ... ... for biopharmaceutical and biotech research and development (R&D), today announced the establishment of ... headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
Breaking Biology News(10 mins):